HeraMED Limited advised that it has entered the United Kingdom, following the launch of its dedicated business to consumer (B2C) website. The launch follows positive feedback from senior medical executives, hospitals and consumers in the United Kingdom and Israel. The expansion into the United Kingdom represents the largest addressable market that HeraMED currently has exposure to. The United Kingdom boasts ~770,000 births per annum and potential success in the region will also provide a strong foundation for growth throughout Europe. HeraMED decided to progress its United Kingdom expansion initiatives following positive feedback it received from discussions with a range of senior obstetricians and gynaecologists at both private hospitals and medical institutions that are part of the UK's National Health Service (NHS). HeraMED has undertaken a number of meetings and product trials within the medical community in the United Kingdom and is confident of endorsement and potential product uptake in the region. Further, the company has established a qualified logistics partner, as well as a digital marketing agency to progress growth during an initial soft launch phase. The company will advance discussions with medical institutions, private hospitals and government organizations to progress its `top down' strategy throughout the United Kingdom and Europe more broadly. HeraMED will aim to establish a pilot trial with a hospital in the UK, as well as pursue agreements with distribution partners in the region. The Company looks forward to updating shareholders as these developments materialise.